Dongwha Pharm Q1 2026 Operating Profit Surges 395%, Consolidated Sales Up 3.9%

Consolidated Q1 2026 sales KRW 130,614M (+3.93% YoY), operating profit KRW 11,228M (+394.83%), significant earnings improvement
Consolidated net profit attributable to parent KRW 10,019M, separate sales KRW 105,612M, separate operating profit KRW 12,104M
Pharmaceutical segment sales KRW 104,818M (vs KRW 98,247M), medical device (Medyssey) KRW 7,415M, drug distribution chain (TS Care) KRW 17,721M (continued losses)
Total assets KRW 647,922M, total liabilities KRW 238,274M, total equity KRW 409,648M (including non-controlling interests)
Credit rating A+ (Korea Rating Data) maintained; no share buyback, cancellation, or dividend announcements
Key license-in contracts: LT1001 (analgesic) awaiting re-approval after rejection; ECCLOCK gel (hyperhidrosis) launched; LUCONAC Solution (nail fungus) under approval
Subsidiary TS Care (Vietnam pharmacy chain, 55.99% stake) recorded net loss of KRW 1,779M, reflected in non-controlling interests
R&D expenses KRW 5,418M (4.17% of sales); improved new drug DW6017 (P-CAB) applied for approval; multiple health functional food pipelines
Consolidated cash and cash equivalents KRW 10,505M; short-term borrowings KRW 90,337M; long-term borrowings KRW 15,134M